Search for biomarkers in chronic obstructive pulmonary disease

Nicholas, Ben

doi:10.1097/mcp.0b013e32835ceee5

Cited by 9 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could for example be achieved by large scale analysis of proteins (proteomics) or metabolites (metabolomics). Such studies have shown to result in protein fingerprints, which potentially could be used to investigate the pathophysiology of COPD in more detail, stratify patients for the treatment of COPD and provide a tool to therapy response [33,34]. Despite these promising results, it is important to realize that also this type of biomarkers should properly be validated and preferably underpinned by a mechanistic understanding of the changes in these profiles, before they can be utilized reliably as markers for disease progression or assessment of treatment effects.…”

Section: Discussionmentioning

confidence: 99%

Reproducibility of biomarkers in induced sputum and in serum from chronic smokers

Zuiker

Kamerling

Morelli

et al. 2015

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Reproducibility of biomarkers in induced sputum and in serum from chronic smokers

Zuiker

Kamerling

Morelli

et al. 2015

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

“…As the identification of biomarkers in COPD is a developing field, a topic of active research is the utility of biomarkers in improving subphenotyping of COPD patients 24. CCL-18 is mainly expressed by monocytes/macrophages and immature dendritic cells.…”

Section: Discussionmentioning

confidence: 99%

Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization

Dilektaşlı¹,

Cetinoglu²,

Uzaslan³

et al. 2017

COPD

View full text Add to dashboard Cite

IntroductionChemokine (C-C motif) ligand 18 (CCL-18) has been shown to be elevated in chronic obstructive pulmonary disease (COPD) patients. This study primarily aimed to evaluate whether the serum CCL-18 level differentiates the frequent exacerbator COPD phenotype from infrequent exacerbators. The secondary aim was to investigate whether serum CCL-18 level is a risk factor for exacerbations requiring hospitalization.Materials and methodsClinically stable COPD patients and participants with smoking history but normal spirometry (NSp) were recruited for the study. Modified Medical Research Council Dyspnea Scale, COPD Assessment Test, spirometry, and 6-min walking test were performed. Serum CCL-18 levels were measured with a commercial ELISA Kit.ResultsSixty COPD patients and 20 NSp patients were recruited. Serum CCL-18 levels were higher in COPD patients than those in NSp patients (169 vs 94 ng/mL, P<0.0001). CCL-18 level was significantly correlated with the number of exacerbations (r=0.30, P=0.026), although a difference in CCL-18 values between infrequent and frequent exacerbator COPD (168 vs 196 ng/mL) subgroups did not achieve statistical significance (P=0.09). Serum CCL-18 levels were significantly higher in COPD patients who had experienced at least one exacerbation during the previous 12 months. Overall, ROC analysis revealed that a serum CCL-18 level of 181.71 ng/mL could differentiate COPD patients with hospitalized exacerbations from those who were not hospitalized with a 88% sensitivity and 88.2% specificity (area under curve: 0.92). Serum CCL-18 level had a strong correlation with the frequency of exacerbations requiring hospitalization (r=0.68, P<0.0001) and was found to be an independent risk factor for hospitalized exacerbations in the multivariable analysis.ConclusionCCL-18 is a promising biomarker in COPD, as it is associated with frequency of exacerbations, particularly with severe COPD exacerbations requiring hospitalization, as well as with functional parameters and symptom scores.

show abstract

Inflammatory biomarkers in chronic obstructive pulmonary disease

Fattouh

Alkady

2014

Egyptian Journal of Chest Diseases and Tuberculosis

View full text Add to dashboard Cite

Search for biomarkers in chronic obstructive pulmonary disease

Abstract: Biomarker identification in COPD is still a developing field, with increasing interest in patient phenotyping probably reflecting the challenges of biomarker development in a complex disease.

Cited by 9 publications

References 38 publications

Reproducibility of biomarkers in induced sputum and in serum from chronic smokers

Reproducibility of biomarkers in induced sputum and in serum from chronic smokers

Serum CCL-18 level is a risk factor for COPD exacerbations requiring hospitalization

Inflammatory biomarkers in chronic obstructive pulmonary disease

Contact Info

Product

Resources

About